As of November 10, 2026, Zai Lab Ltd has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 21, 2026 (Form 8-K, May 21, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Zai Lab Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Zai Lab Ltd reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-21. Every row below is cited to the filing it comes from, and this page adds each new change as Zai Lab Ltd files it.
Also on the record for Zai Lab Ltd
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Form D, private offering | $249.93M sold | Form D page | Source |
| June 11, 2026 | Stake report, Schedule 13G, by Chen Yu | 5.3% of the class | 5%+ stakes | Source |
| April 6, 2026 | Stake report, Schedule 13G, by RA Capital Management, L.P. | 5.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G, by RTW Investments, LP | 6.3% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Capital World Investors | 0.2% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Qiming Corporate GP IV, Ltd. | 4.4% of the class | 5%+ stakes | Source |
| February 10, 2026 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 4.3% of the class | 5%+ stakes | Source |
| February 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 3.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by RTW Investments, LP | 2.1% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G, by Wellington Management Group LLP | 6% of the class | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 6.4% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G, by RTW Investments, LP | 5.1% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Zai Lab Ltd now and the warning signs.
Free to see. No signup.
Keep reading
More on Zai Lab Ltd and the records around it.
Zai Lab Ltd elsewhere on the record
- 5%+ stake filings Jun 2026
- Who owns it
Companies that share a holder
- TCG Crossover GP II, LLC also filed stake reports on 21 other companies: ALX Oncology Holdings Inc. (Aug 2026), First Tracks Biotherapeutics, Inc. (Aug 2026), Fulcrum Therapeutics, Inc. (Aug 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Zai Lab Ltd
Get an email when Zai Lab Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Zai Lab Ltd?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Zai Lab Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Zai Lab Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-21 | Reported | not named in the filing | 8-K, 2026-05-21 |
New leaders reset buying decisions — get the Full Report on Zai Lab Ltd: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Zai Lab Ltd, with the record behind each one.
Find candidates like senior executive at Zai Lab LtdEvery change, in the filing's words
Reported
On May 18, 2026, the Board of Directors of Zai Lab Limited (the "Company") determined that Mr. Josh Smiley will cease serving as President and Chief Operating Officer of the Company, effective as of May 18, 2026, and his last day of employment with the Company will be May 22, 2026.
- The responsibilities previously associated with such positions have been assumed by Samantha Du, the Company's Board Chair, Founder and Chief Executive Officer, and other members of the Company's management team.
- Mr. Smiley will receive severance pursuant to his existing employment agreement, subject to his execution of a customary release.
Tools for this story
Each opens in a new tab, filled in for Zai Lab Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.